Glucosi + Natrii Chlorati Viaflo Baxter Polska

Glucosi + Natrii Chlorati Viaflo Baxter Polska is an injectable solution that combines glucose and sodium chloride. The product is supplied as a sterile intravenous (IV) injection solution, with the specific concentration of each component not disclosed in the public label. It is manufactured by Baxter Polska for the European market and is available by prescription only. The formulation is intended for fluid and electrolyte replacement in clinical settings.

Glucosi + Natrii Chlorati Viaflo Baxter Polska is used when patients require rapid restoration of fluid volume and electrolyte balance. It is commonly administered in hospital settings under medical supervision.

- Treatment of dehydration caused by vomiting, diarrhea, or fasting - Replacement of sodium and chloride losses after surgery or trauma - Management of hypoglycemia when oral glucose is not feasible - Supportive therapy during peri‑operative fluid management - Adjunctive use in patients receiving parenteral nutrition

Side effects may occur with any intravenous solution, although many patients tolerate the product without problems.

Common: - Mild local irritation at the infusion site - Transient increase in blood glucose levels - Slight electrolyte imbalance (e.g., hypernatremia) if administered in large volumes - Nausea or mild abdominal discomfort - Headache or dizziness during rapid infusion

Serious: - Severe hyperglycemia requiring medical intervention - Significant hypernatremia leading to neurological symptoms - Allergic reaction such as urticaria or anaphylaxis - Fluid overload causing pulmonary edema - Electrolyte disturbances causing cardiac arrhythmias

Healthcare professionals should assess patient-specific factors before initiating therapy with Glucosi + Natrii Chlorati Viaflo Baxter Polska.

- Verify baseline blood glucose and electrolyte levels prior to infusion - Adjust infusion rate in patients with cardiac or renal impairment - Monitor for signs of fluid overload, especially in elderly or critically ill patients - Use caution in patients with known hypersensitivity to any component of the solution - Avoid rapid bolus administration unless clinically indicated - Ensure compatible IV tubing and solutions to prevent precipitation

Potential drug interactions should be considered to maintain safety and therapeutic effectiveness.

Avoid: - Co‑administration with hypertonic saline solutions that may exacerbate hypernatremia - Concurrent use of high‑dose insulin without glucose monitoring, which can precipitate severe hypoglycemia

Use with caution: - Diuretics that alter sodium balance (e.g., furosemide) - Medications that affect glucose metabolism such as glucocorticoids or beta‑blockers - Other intravenous fluids containing electrolytes, to prevent cumulative electrolyte excess - Blood pressure–lowering agents, as rapid volume expansion may affect hemodynamics